Multivariate analysis for PFS (treatment adjusted)
| Prognostic factors . | HR . | 95% CI . | P . | P* . |
|---|---|---|---|---|
| Fludarabine-refractoriness | 3.36 | 1.65-6.86 | .001 | .004 |
| TP53 mutation | 1.81 | 1.02-3.21 | .043 | .077 |
| Multiple-hit profile | 2.24 | 1.24-4.03 | .007 | .015 |
| Prognostic factors . | HR . | 95% CI . | P . | P* . |
|---|---|---|---|---|
| Fludarabine-refractoriness | 3.36 | 1.65-6.86 | .001 | .004 |
| TP53 mutation | 1.81 | 1.02-3.21 | .043 | .077 |
| Multiple-hit profile | 2.24 | 1.24-4.03 | .007 | .015 |
Including variables with P < .1 in univariate analysis (fludarabine refractoriness, TP53 mutation, ATM mutation, multiple-hit profile and trial).
After bootstrapping process (1000 samples).